Patents by Inventor Philippe Morain

Philippe Morain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100197740
    Abstract: The invention relates to a method of screening compounds having anti-amyloid properties. The method of screening compounds that are capable of dissociating or preventing high-affinity complexes between ?-amyloid peptides and nicotinic acetylcholine receptors of human cortical tissues makes it possible to rapidly identify compounds intended for the curative and/or preventive treatment of neurodegenerative diseases, especially Alzheimer's disease.
    Type: Application
    Filed: August 16, 2007
    Publication date: August 5, 2010
    Applicant: LES LABORATOIRES SERVIER
    Inventors: Hoau-Yan Wang, Philippe Morain, Caryn Thibierge
  • Patent number: 5776949
    Abstract: A compound of formula (I): ##STR1## in which: R.sub.1, R.sub.2, R.sub.3, which are identical or different, represent hydrogen, halogen, alkyl, nitro, cyano, aminosulfonyl, imidazolyl, or pyrrolyl, or alternatively, when two of them are situated on adjacent carbons, may form with the carbon atoms to which they are attached a benzene ring on C.sub.3 -C.sub.7 cyloalkylR.sub.4 represents hydroxyl, alkoxy, phenoxy, or amino,their isomers as well as their addition salts with a pharmaceutically-acceptable base, and medicinal products containing the same which are useful as inhibitors of the the pathological phenomena linked to hyperactivation of the neurotransmission pathways by the excitatory amino acids.
    Type: Grant
    Filed: July 10, 1997
    Date of Patent: July 7, 1998
    Assignee: Adir et Compagnie
    Inventors: Alex Cordi, Patrice Desos, Jean Lepagnol, Philippe Morain, Pierre Lestage
  • Patent number: 5536719
    Abstract: A compound of formula (I): ##STR1## in the form of its S enantiomer, its addition salts with a pharmaceutically acceptable acid or base and medicinal product containing the same are useful for the treatment or prevention of pathologies associated with dysfunction of glutamatergic neurotransmission.
    Type: Grant
    Filed: July 11, 1995
    Date of Patent: July 16, 1996
    Assignee: Adir et Compagnie
    Inventors: Alex Cordi, Michael Spedding, Bernard Serkiz, Jean Lepagnol, Patrice Desos, Philippe Morain